A press article detailing the exciting new clinical results of CHIMES-E study showing the persisting benefits of NeuroAiD in post-stroke recovery was published online on Medscape.com

Moleac is pleased to announce the release of the CHIMES-E study results published online in the journal Cerebrovascular Diseases. It provides convincing data on NeuroAiD which confirm its persistent long-term benefits on patients recovery after an ischemic stroke. The CHIMES-E study results were first announced by Prof. Christopher Chen (CHIMES-E co-principal investigator) during the European Stroke Organization Conference (ESOC 2015) in Glasgow, April 1719, as part of the Scientific Program during the Clinical Trial session.

A press article detailing the exciting latest clinical data on vascular events reduction after a stroke has been published in the magazine “Actifs”

Singapore, 21st October 2013 – Early vascular events are an important cause of morbidity and mortality in the first three months after a stroke. The CHIMES Study is a placebo-controlled trial of NeuroAiD™, having included 1099 patients with ischemic stroke and receiving appropriate secondary prevention treatments. The frequency of early cardiovascular events and deaths during the 3-month follow-up was significantly halved in the NeuroAiD™, group (p=0.025) without an increase in bleeding rate and non-vascular deaths.

938LIVE is a poplar news-focused radio station. ‘Body & Soul’, since it first aired in 2007, has been Singapore’s only dedicated daily health radio talk-show.

• CHIMES Society, a unique international partnership of experts in strokes undertakes first large-scale endeavour to investigate the use of a treatment derived from natural substances in stroke management.
• Rigorous study shows ischemic stroke patients of intermediate severity who take NeuroAiD at acute stage had an 11 % increase in the odds of achieving independence and being able to perform daily activities at the end of three months.
• Effect was even greater when NeuroAiD was started beyond 48 hours after stroke onset, with an increase of 39%.

Singapore, March 19 2013: Authors of a medical paper published in this month’s Cerebrovascular Diseases journal found that NeuroAiD™ significantly improves patients’ independence after suffering a stroke compared to other control groups. During the studies stroke patients taking NeuroAiD™ were twice as likely able to take care of themselves and speak freely. The study also showed that NeuroAiD™ improved patients’ chances of performing daily activities after stroke.

“Neuropharmacology” published a paper establishing NeuroAiD’s reparativeeffects on global cerebral ischemia.

We are happy to announce that Prof. Michel Lazdunski, vice president research of Moleac, has been awarded one of the most prestigious international awards – the 2011 Gold Medal of the Jung Foundation for Science and Research, for his work on ion channels.

Moleac Pte Ltd has been granted the Emerging Company of the Year 2010 Award, by Biospectrum, the leading integrated media platform for the Life Science Industry in Asia Pacific.

The January issue of “Neuropharmacology”, publishes the article entitled “Neuroprotective and Neuroproliferative Activities of NeuroAiD”, reporting pharmacological data establishing NeuroAiD (MLC 601) protective effects on neuronal and brain injuries as well as its effectiveness in neurological functions recovery.

An important confirmation of Moleacs outstanding performance in 2008.

A world-renown scientific leader is now in charge of the study on NeuroAiD mechanism of action.

A mixture derived from Chinese medicine on trial. One of the most prestigious magazine for doctors in France has paid special attention to NeuroAid&trade.